Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group.

@article{Sabbah1999ComparisonOT,
  title={Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group.},
  author={Ahmad Sabbah and J. Van Daele and A Gardiner Wade and Paul Ben-Soussen and Pierre Attali},
  journal={Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology},
  year={1999},
  volume={83 4},
  pages={319-25}
}
BACKGROUND Mizolastine is a potent and selective H1-receptor antagonist with additional anti-allergic properties. OBJECTIVE The aim of this European multicenter, randomized, double-blind study was to compare the efficacy of mizolastine 10 mg (n = 122), cetirizine 10 mg (n = 125), and placebo (n = 128) once daily for 28 days in patients with seasonal allergic rhinoconjunctivitis (SAR), with focus on the onset of action. METHODS Symptoms were evaluated by the investigator using a total… CONTINUE READING